dsm wrote:When I am thinking of UARS I am going by Barry Krakow's definition and that I suspect is where some people will have diverging views.
I suspect most of the medical community currently diverge with Dr. Krakow's definition of UARS. In that thread you linked to earlier, Dr. Krakow contended flow limitation was sole criterion for UARS. Not to still sound playful or cheeky.... But I have yet to see other credible researchers claim that. Rather, Dr. Krakow's definition of UARS essentially implicates the entire human population of having either constant or prolifically recurring UARS.
The rest of the medical community who argue for the existence of UARS as a unique condition, tend to stick with what that letter "S" signifies: "
Syndrome", which by definition entails an entire constellation of symptoms. So the basis of inquiry for most of the medical research community embracing UARS as a possible medical condition seems to be built on that central premise of extensive symptomology---and not just flow limitations. Then based on that more extensive UARS symptomology, various characteristic/candidate etiologies, pathologies, pathophysiologies, and treatment methods are typically considered that extend beyond the premise:
"You have flow limitations: therefore you have UARS". I mean no disrespect to Dr. Krakow, because I think his position may actually be tenable, although I personally disagree with it. Then as gobears stated, many in the medical community do not even think that UARS, as a unique condition, exists. Rather some contend that UARS is simply a variant or lesser severity of obstructive SDB failing to meet any criteria as either a unique condition or symptomatically-based syndrome.
So I personally think it would be next to impossible to syllogistically determine if SV can successfully treat UARS with that grotesque lack of understanding in the medical community regarding just what UARS might or might not be.
However, the subject of SV's very narrow recent-averaging time window has come up in light of gobears' own UARS-related sustained temporal variations above. Doug, when you say "good point" are you saying that you think SV's narrow flow-targeting window can consistently and efficiently counter those sustained variations in flow reduction that gobears related above? If so, I have to politely disagree with both of you.
Here is the caveat of short-sighted SV's lacking temporal-variable based flow-maintenance demonstrated:
Stephen E. Brown, MD, DABSM wrote:In another patient, undertitration occurred as the technologist adjusted the EEP for apneas and hypopneas, but did not adequately increase the pressure for residual RERAs.
http://www.sleepreviewmag.com/issues/ar ... -06_03.asp
And if it's okay, I'll paraphrase my above statement to highlight the technology being discussed rather than the manufacturers:
The inherent problem with SV's narrow-time-window based flow averaging and targeting: under-addressed sustained downward flow-skews can prolifically be averaged, targeted, and repeated throughout a sleep session.
Unfortunately,
sustained flow reductions that the body does not manage to spontaneously correct on its own, can stay prolifically under-treated when relying on a several-minute narrow flow targeting time window. Again, that's why the manufacturers contraindicate hypoventilation syndromes and that's why the manufacturers ask that the obstructive SDB component be manually addressed with a fixed pressure bias. Otherwise clinicians may run into the situation Dr. Brown describes above.